Pekin Life Insurance Company (PKIN) Fair Value & Analysis
Financial Services · US · Market cap $192M
Fair value as of: Jun 26, 2026
Analysis
Pekin Life Insurance Company (PKIN) currently trades at $11.75, while our model-based Fair Value estimate is $5.23 — implying the stock looks roughly 55.5% overvalued today. We read business quality at 95/100 (high quality), in the Financial Services sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
Pekin Life Insurance Company operates as a life and accident, and health insurance company in the United States. The company offers auto and home insurance products; pre-need life insurance; life insurance products, annuities, and funeral preplanning products; health insurance products; and business insurance products, including business auto, business property, general liability, and workers' compensation insurance products. It also provides group life, dental, accidental death and dismemberment, and short-term disability, as well as voluntary products and medicare supplement insurance. It sells its insurance products primarily through independent agents. Pekin Life Insurance Company was founded in 1921 and is headquartered in Pekin, Illinois. Pekin Life Insurance Company operates as a subsidiary of Farmers Automobile Insurance Association.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Pekin Life Insurance Company (PKIN) undervalued?
What is the fair value of PKIN?
What is the quality score of PKIN?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.